Navigation Links
Nektar Therapeutics Announces Second Quarter 2008 Results
Date:8/6/2008

p>Loss from operations (33,358) (27,988) (75,247) (53,957)

Non-operating income (expense):

Interest income 3,190 5,452 8,203 10,925

Interest expense (3,929) (4,702) (7,847) (9,635)

Other expense, net 769 (22) 1,071 (16)

Total non-operating income 30 728 1,427 1,274

Loss before provision for income

taxes (33,328) (27,260) (73,820) (52,683)

Provision for income taxes 47 250 260 500

Net loss $(33,375) $(27,510) $(74,080) $(53,183)

Basic and diluted net loss per

share $(0.36) $(0.30) $(0.80) $(0.58)

Shares used in computing basic and

diluted net loss per share 92,400 91,804 92,365 91,630

NEKTAR THERAPEUTICS

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

June 30, December 31,

2008 2007

(unaudited) (1)

ASSETS

Current assets:

Cash and cash equivalents $31,829 $76,293

Short-term investments 342,078 406,060

Accounts receivable, net of

allowance 12,067 21,637

Inventory 10,166 12,187

Other current assets 13,988 7,106

Total current assets 410,128 523,283

Property and equipment, net 114,229 114,420
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
2. Nektar Therapeutics Announces First Quarter 2008 Results
3. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
4. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
5. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
6. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
7. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
8. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
9. Nektar Therapeutics Announces Third Quarter 2007 Financial Results
10. Nektar to Announce Third Quarter 2007 Financial Results on Wednesday, November 7, 2007, After the Close of U.S. Financial Markets
11. InteKrin Therapeutics Announces $20 Million Series C Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... study published today in Genes & Development ... Sciences Centre,s DNA Replication group, in collaboration with ... intricate mechanisms involved in the enzyme that governs ... sophisticated system using synthetic, chemical and structural biology ... involved in duplicating genetic information embraces DNA through ...
(Date:7/31/2014)... LDM Global ( http://www.ldmglobal.com ) announces the ... simplified and predictable with fixed fees across the board, ... international provider of legal discovery management services for law ... apparent that both the courts and legal counsel alike ... complex pricing structure that plagues the litigation support industry. ...
(Date:7/31/2014)... 2014 The Alaska Center for ... new dentist Dr. Jonathan Oudin, DDS, who will begin ... in Barrow, Alaska, for three years. According to Teresa ... Dr. Oudin to help take on new patients. , ... continue growing and serving the greater Anchorage metro community," ...
(Date:7/31/2014)... 2014 (HealthDay News) -- Transplant surgeons often feel ... for burnout, a new study suggests. Nearly ... reported having a low sense of personal accomplishment ... emotionally exhausted, researchers found. "Burnout is common ... study co-author Dr. Marwan Abouljoud, director of the ...
(Date:7/31/2014)... algorithm aimed to diagnose pediatric patients with suspected ... scans, without affecting diagnostic accuracy, Mayo Clinic Children,s ... published in the journal Surgery . , ... acute abdominal pain in children. Appendicitis occurs when ... CT scans are often used to diagnose acute ...
Breaking Medicine News(10 mins):Health News:Molecular gate that could keep cancer cells locked up 2Health News:LDM Global Announces Predictable Simple Fixed-Fee Pricing 2Health News:Dr. Jonathan Oudin to Join Alaska Center for Dentistry at Wasilla Location 2Health News:Burnout Common Among Transplant Surgeons, Study Reveals 2
... to more false positives, additional work-ups , , THURSDAY, Jan. ... estimating glomerular filtration (eGFR) rates from routine blood work ... with chronic kidney disease, U.S. researchers report. , The ... kidneys over time, and its formula factors in measures ...
... BETHESDA, Md., Jan. 29 /PRNewswire-Asia/ -- Chindex International, Inc.,(Nasdaq: ... of western healthcare,products and services in the People,s Republic ... third quarter 2009 financial results on Monday,February 9, 2009, ... 8:00 am ET that day to discuss financial results. ...
... Meditation technique may help keep discomfort at bay, study ... Zen meditation appears to reduce sensitivity to moderate pain ... "Previous studies had already shown that teaching patients with ... no one had examined how these effects might come ...
... management system designed to meet unique supply management ... Fla., Jan. 29 Omnicell, Inc. (Nasdaq: ... solutions to acute healthcare facilities, and Shands HealthCare ... chain management systems (formerly known as OptiFlex SS) ...
... and FORT LAUDERDALE, Fla., Jan. 29 Houlihan Smith,& ... into Tri-Tech Health, LLC, (Tri-Tech Health) as announced by,Charles ... The,advisory services were led by Houlihan Smith Managing ... , "We have been working ...
... Cholera Outbreak STAMFORD, Conn., Jan. 29 AmeriCares is ... in an effort to stem a deadly cholera outbreak ... outbreak is one of Africa,s deadliest in 15 years ... is at risk. With limited medical resources and dismal ...
Cached Medicine News:Health News:Kidney Function Test May Not Be Cost-Effective 2Health News:Chindex International, Inc. to Report Fiscal Third Quarter 2009 Financial Results 2Health News:The Zen Way to Pain Relief 2Health News:The Zen Way to Pain Relief 3Health News:The Zen Way to Pain Relief 4Health News:Shands HealthCare Increases Operational Efficiency in Surgical Suites With Omnicell Supply Systems 2Health News:Shands HealthCare Increases Operational Efficiency in Surgical Suites With Omnicell Supply Systems 3Health News:Houlihan Smith Arranges Equity Investment Into Tri-Tech Health, LLC 2Health News:AmeriCares Doubles Aid to Zimbabwe 2
(Date:7/31/2014)... Surgical Company (NASDAQ: STAA ) a leading ... systems for the eye today reported revenue for the ... a 10% increase over $18.2 million reported for the ... revenues grew 11% during the second quarter of 2014 ... of foreign currency exchange reduced sales by $0.1 million ...
(Date:7/31/2014)... 31, 2014 Xencor Inc. (NASDAQ: ... engineered monoclonal antibodies for the treatment of autoimmune ... reported financial results for the second quarter ended June ... business highlights. "In the second quarter, ... Society 2014 International Conference (ATS) demonstrating three novel ...
(Date:7/31/2014)... July 31, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... on its pipeline and new product development efforts. In ... initiate a Phase 2a study of AZ-002 (Staccato ... the management of patients with acute repetitive seizures. ... -based product candidates for development - AZ-008 and ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6
... NEW CENTERS AND TO ... INCREASE AWARENESS AMONG CARDIOLOGISTS, PLEASANTON, Calif., April 21 ... mechanical,circulatory support therapies to save, support and restore failing hearts,said ... (PreMarket,Approval) application, allowing the use of its HeartMate II LVAS ...
... April 21 A new study funded by,Health ... correlation,between dietary consumption of the omega-3 DHA* and ... Universite Laval,researchers and published in the Journal of ... pregnancy boosts an infant,s sensory,cognitive, and motor development., ...
Cached Medicine Technology:Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation 2Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation 3Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation 4Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation 5Pregnant Women Need Omega-3 to Boost Infant Development 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: